Table 2.

Patients receiving oritavancin to treat culture-positive osteomyelitis—results per pathogen, methicillin-sensitive Staphylococcus aureus

Reference	Sex/age (years)	Site of infection	Antimicrobials prior to oritavancin	Oritavancin dosing regimen	Concomitant antimicrobials	Outcome	Time of follow-up	Adverse events
Schulz et al. [40]	F/76	Not specified	None	1200 mg twice a week × 2 doses	Transitioned to doxycycline × 10 days	Clinical improvement	2 weeks	Anemia and leukopenia in 1 patient
Stewart et al. [42]	F/26	Sacral joint	Cefazolin; pip/tazo	1200 mg × 1 dose	None	Failure	6 weeks	None reported
Delaportas et al. [39]	F/49	Right tibia	None	1200 mg weekly × 6 doses	None	Clinical success	1, 4, 8, 12, 24, and 40 weeks	None reported
CHROME registry [46]	M/60	Not specified	Amox/clav, vancomycin, cefazolin/cephalexin	1200 mg × 1	None	Clinical cure	N/A	None reported
	F/98	Not specified	Ceftriaxone, levofloxacin	1200 mg × 1 (did not finish)	Ciprofloxacin	Clinical cure	N/A	None
	M/46	Not specified	Amoxicillin	1200 mg × 6 doses every 6–8 days	None	Clinical cure	N/A	None
	F/36	Not specified	Amp/sul, ceftriaxone, TMP/SMX, vancomycin, cefazolin, cephalexin	1200 mg × 3 doses every 14 days	None	Clinical cure	N/A	None

F female, M male, TMP/SMX trimethoprim/sulfamethoxazole, amox/clav amoxicillin/clavulanic acid, amp/sul ampicillin/sulbactam, pip/tazo piperacillin/tazobactam, N/A information not available